These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 34734390)

  • 1. Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.
    Garcia-Romeu A; Darcy S; Jackson H; White T; Rosenberg P
    Curr Top Behav Neurosci; 2022; 56():287-317. PubMed ID: 34734390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of psychedelics for the treatment of Alzheimer's disease and related dementias.
    Winkelman MJ; Szabo A; Frecska E
    Eur Neuropsychopharmacol; 2023 Nov; 76():3-16. PubMed ID: 37451163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression.
    Pilozzi A; Foster S; Mischoulon D; Fava M; Huang X
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal Behavior in Psychedelic Research.
    Odland AU; Kristensen JL; Andreasen JT
    Pharmacol Rev; 2022 Oct; 74(4):1176-1205. PubMed ID: 36180111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways.
    Sinha JK; Trisal A; Ghosh S; Gupta S; Singh KK; Han SS; Mahapatra M; Abomughaid MM; Abomughayedh AM; Almutary AG; Iqbal D; Bhaskar R; Mishra PC; Jha SK; Jha NK; Singh AK
    Ageing Res Rev; 2024 Apr; 96():102211. PubMed ID: 38307424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT
    Sekssaoui M; Bockaert J; Marin P; Bécamel C
    Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic-inspired approaches for treating neurodegenerative disorders.
    Saeger HN; Olson DE
    J Neurochem; 2022 Jul; 162(1):109-127. PubMed ID: 34816433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer's Disease and Related Dementias.
    Peterson A; Largent EA; Lynch HF; Karlawish J; Sisti D
    AJOB Neurosci; 2023; 14(2):107-123. PubMed ID: 36476106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the 5-HT
    Cameron LP; Benetatos J; Lewis V; Bonniwell EM; Jaster AM; Moliner R; Castrén E; McCorvy JD; Palner M; Aguilar-Valles A
    J Neurosci; 2023 Nov; 43(45):7472-7482. PubMed ID: 37940583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin 2A Receptor (5-HT
    Duan W; Cao D; Wang S; Cheng J
    Chem Rev; 2024 Jan; 124(1):124-163. PubMed ID: 38033123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.
    Meccia J; Lopez J; Bagot RC
    Psychopharmacology (Berl); 2023 Jan; 240(1):27-40. PubMed ID: 36564671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
    Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
    Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained effects of single doses of classical psychedelics in humans.
    Knudsen GM
    Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics action and schizophrenia.
    Maćkowiak M
    Pharmacol Rep; 2023 Dec; 75(6):1350-1361. PubMed ID: 37899392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
    Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
    J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelics and Neural Plasticity: Therapeutic Implications.
    Grieco SF; Castrén E; Knudsen GM; Kwan AC; Olson DE; Zuo Y; Holmes TC; Xu X
    J Neurosci; 2022 Nov; 42(45):8439-8449. PubMed ID: 36351821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.
    Barrett FS; Carbonaro TM; Hurwitz E; Johnson MW; Griffiths RR
    Psychopharmacology (Berl); 2018 Oct; 235(10):2915-2927. PubMed ID: 30062577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
    Vollenweider FX; Kometer M
    Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The acute effects of classic psychedelics on memory in humans.
    Healy CJ
    Psychopharmacology (Berl); 2021 Mar; 238(3):639-653. PubMed ID: 33420592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.